Gauss Health Uses AI and Blood Data to Revolutionize Personalized Supplementation in Brazil

Gauss Health is disrupting the traditional wellness market by launching an AI driven platform that crafts supplements based on individual biology. Founded by tech entrepreneur Thiago Lima, the startup analyzes over 150 blood biomarkers to create high precision formulas. This approach aims to replace generic off the shelf vitamins with science backed personalization that adapts to the user.

The process begins when users upload recent blood test results to the Gauss platform for a comprehensive digital analysis. An advanced AI system cross-references these lab values with lifestyle habits and specific health goals like longevity or performance. Every recommendation undergoes a final review by a medical professional to ensure clinical safety and accuracy before production begins.

Once validated, personalized supplements are manufactured with premium active ingredients and shipped directly to the customer. Unlike static formulas found in retail stores, these protocols are living documents that evolve as the user’s health metrics change over time. Monitoring continues through smart integrations and direct support provided via WhatsApp to track progress.

Thiago Lima, previously the creator of LinkAPI, draws inspiration from successful US healthtech firms while focusing on the Brazilian compounding pharmacy sector. He envisions Gauss as a digital transformation agent similar to how Nubank revolutionized traditional banking systems. The company has already gained traction among elite athletes and built a substantial waitlist ahead of its wider release.

Early users report significant improvements in energy levels and the correction of hidden nutritional deficiencies. By providing a clear link between supplement intake and blood work results, the platform offers a level of traceability previously unavailable to consumers. This data first mindset helps users avoid unnecessary spending on ineffective products that do not match their biology.

Operating within strict regulatory frameworks, Gauss ensures that all suggestions are for preventive monitoring and wellness optimization. The startup plans to expand its data inputs by integrating wearable technology like smartwatches into its analysis engine. Future growth will be supported by an upcoming venture capital round scheduled for 2026 to scale operations globally.